HC Wainwright & Co. Maintains Buy on Zentalis Pharma, Lowers Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on Zentalis Pharma (NASDAQ:ZNTL), but has lowered the price target from $55 to $46.

November 07, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zentalis Pharma's price target has been lowered from $55 to $46 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target could potentially indicate a less optimistic outlook for Zentalis Pharma's stock in the short term. However, the maintained 'Buy' rating suggests that the analyst still sees potential upside, which could balance out any negative impact from the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100